Back to Peptides
VIP
Immune ModulationVasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that modulates immune response, dilates pulmonary vessels, and protects neural tissue. It is being studied for its potential role in treating pulmonary hypertension, COVID-19 respiratory failure, inflammatory and autoimmune disorders, and migraines.
Reconstitute
2 mL BAC + 5mg vial
25 mcg/unit
Daily Range
50–200 mcg Subcutaneous (SQ)
daily
Standard Dose
100 mcg
Cycle
4–8 weeks
then reassess
VIPVasoactive Intestinal Peptideimmune modulationpulmonary hypertensionneuroprotection
Dosing & Reconstitution Guide
In rodent studies, VIP has been administered at 5–50 μg/kg via intraperitoneal or intravenous injection. These doses are investigational and used only in controlled research settings.
Standard / Gradual Approach
standardPhaseDoseVolume
Week 1100mcg
Week 2200mcg
Week 3300mcg
Week 4500mcg
Protocol Summary
Subcutaneous (SQ): daily · Dose range 50–200 mcg with gradual titration
Intranasal: 1 spray per nostril, 3-4x daily · Dose range 50–200 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Typically 100 mcg daily for 4–6 weeks for autoimmune or pulmonary inflammatory conditions. May repeat cycles as needed.
Intranasal
Useful for direct CNS and respiratory targeting; used daily or in cycles for neuroinflammation and MCAS protocols.
🧪 Quick Start
BAC Water
2 mL
Potential Benefits & Use Cases
Vasoactive Intestinal Peptide (VIP) is a research-use-only compound. It is not approved for human or veterinary use. All content is for educational and scientific reference only
Studied for reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α) in immune cells
Explored in rodent models for protection against autoimmune inflammation
Investigated for lung and respiratory support in asthma and pulmonary hypertension models
May regulate circadian rhythm and brain-gut signaling in preclinical research
Interest in potential synergy with peptides like PACAP in neuroimmune regulation
Clinical data Strong preclinical Limited data
Mechanism of Action
→Binds to VPAC1 and VPAC2 receptors on immune, pulmonary, and neural tissues
→Suppresses pro-inflammatory cytokines (e.g., TNF-α, IL-6)
→Enhances T-regulatory cell function and dampens Th1/Th17 responses
→Acts as a neuropeptide with protective effects in CNS
Lifestyle & Optimization
timing
Intranasal or SubQ as prescribed. Consistent schedule.
diet
Anti-inflammatory diet (Mediterranean style).
exercise
Exercise moderately 3–4 times weekly.
sleep
Sleep 7–9 hours nightly for immune recovery. Reduce stress through meditation.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Side Effects & Safety
Common Side Effects
• Nasal irritation with intranasal administration
• Mild flushing or hypotension
• Headache
Contraindications & Warnings
• May induce migraine in susceptible individuals
• Use cautiously in patients with asthma or vascular instability
Long-Term Safety Data
• Safety under long-term use still under evaluation; neuroprotective potential is under investigation
🧮 Dose Calculator
Concentration
25.0
mcg/unit
Draw Volume
20
units (0.200 mL)
For a 500 mcg dose, draw 20 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
Moderate bioavailability; slow systemic uptake and short half-life
Oral Administration
Poor; rapidly degraded by enzymes
Intranasal
Good for CNS and respiratory effects; bypasses GI degradation
Half-Life
5–10 minutes
Degradation
Degraded by plasma and tissue peptidases
Tissue Specificity
Targets lungs, immune cells, CNS, and vasculature
⚗️
Peptide Details
Molecular Weight
3327.9
Formula
C147H237N43O42S
Sequence
HSDAVFTDNYTRLRKQMAVKKYLNSILN
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
Store lyophilized powder at 2-8°C
Reconstituted (Mixed)
After reconstitution, maintain at 2-8°C and use within 14-28 days. For intranasal use, transfer to spray bottle immediately.